Senior Research Manager, Corning Incorporated　

Biography of Dr. Ye Fang 

Titles:

Pathway Medicine and New Generation Drug Discovery Technologies 

Abstract:

Drug discovery campaigns have undergone tremendous make-over in the recent years. Modern drug development embraces the “one gene, one drug, one disease” philosophy. As a result, traditional phenotypic assays (e.g., tissue-based measurements) have yielded to high throughput screening (HTS)-compatible molecular characterization assays. However, searching maximally selective drugs for single target-based therapies (“magic bullets”) using HTS has failed to deliver its promise – identification of the best in class drug molecules is mostly achieved by serendipity, rather than rational drug design. To exacerbate this is that many diseases such as cancers are related to pathways; and many drugs if not all have intrinsic ability to bind to multiple targets. This presentation begins with overview of drug discovery and development process, followed by introduction of pathway medicine and new generation enabling technologies, with an emphasis of whole cell sensing technologies.

Ye Fang is a senior research manager of Cellular Biophysics, Science and Technology Division, Corning Inc. He began his career as a chemist. He earned his B.S. in Chemistry Education in 1989 from Hubei University, his M.S. in Physical Chemistry in 1992 from Wuhan University, and his Ph.D. in Physical Chemistry in 1995 from the Institute of Chemistry, Chinese Academy of Sciences in Beijing, China. After one-year postdoctoral research in Physics at University of Vermont, and four year postdoctoral research in Biophysics at Johns Hopkins University School of Medicine, he joined Corning Inc. as a Senior Research Scientist in 2000. He is an author or co-author of 2 books, 14 book chapters, and ~80 research papers and review articles. He also holds 10 patents and has 56 pending patent applications.

Time:

AM 9:00, 14th of Jan 2011

The Forth Floor Meeting Room,  Buliding A